View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

ACNB Corporation Announces Common Stock Repurchase Program

ACNB Corporation Announces Common Stock Repurchase Program GETTYSBURG, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- ACNB Corporation (“ACNB”) (NASDAQ: ACNB), financial holding company for ACNB Bank and ACNB Insurance Services, Inc., announced today that the Board of Directors approved a new plan to repurchase, in open market transactions at prevailing market prices, up to 314,000, or approximately 3.0%, of the outstanding shares of ACNB’s common stock. The amount and timing of any shares repurchased will be evaluated and determined by management in its discretion and will depend upon a number o...

 PRESS RELEASE

AMERANT BANK ANNOUNCES HIRE OF ELLIOT SHAFER AS NEW HEAD OF BUSINESS D...

AMERANT BANK ANNOUNCES HIRE OF ELLIOT SHAFER AS NEW HEAD OF BUSINESS DEVELOPMENT MIAMI, FL, June 09, 2025 (GLOBE NEWSWIRE) -- Amerant Bank, Florida’s bank of choice with a growing presence across South Florida, has named Elliot Shafer as SVP, Head of Business Development. In this key role, Shafer will support Amerant’s growth by identifying, evaluating, and pursuing business opportunities that align with Amerant’s strategic objectives across all lines of business. “We are excited to welcome Elliot to the team,” said Jerry Plush, Chairman and CEO. “His extensive experience in business d...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months ...

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month​ blinded treatment periodFavorable safety and tolerability, particularly when compared to standard of care biologics or JAKsMax response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients who either achieved or were trending toward LDA and ACR50Durable responses for at least two months off drug, ...

 PRESS RELEASE

UFP Technologies to Present and Host 1x1 Investor Meetings at the 15th...

UFP Technologies to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast IDEAS Investor Conference on June 11th in New York, NY NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies (UFPT), today announced Jeffrey Bailly, Chairman and CEO and Ron Lataille, Sr. Vice President & CFO, will present at the East Coast IDEAS Investor Conference on Wednesday, June 11, 2025 at The Westin Times Square in New York, NY. UFP’s presentation is scheduled to begin at 7:55 AM ET. The presentation is webcast and can be accessed through the conference host’s main website: a...

 PRESS RELEASE

UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at th...

UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the Goldman Sachs 46th Annual Global Healthcare Conference NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Jeffrey Bailly, Chairman and CEO, and Ron Lataille, Sr. Vice President & CFO, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025. UFP’s fireside chat is scheduled to begin at 11:20 AM ET. About UFP Technologies, Inc. UFP Technologies is a designer and custom manufacturer of comprehensive solutions for m...

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
BLDR BUILDERS FIRSTSOURCE INC.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
UFPI UFP INDUSTRIES INC.
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
NUVB NUVATION BIO INC (A)
RBLX ROBLOX
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
TCRX TSCAN THERAPEUTICS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
BCAX BICARA THERAPEUTICS INC.
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Dylan Shindler
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a ...

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15p...

UFP Technologies Inc: 1 director

A director at UFP Technologies Inc sold 1,473 shares at 220.123USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch